Interaction of Calcium Antagonists with β-Adrenoceptor Blocking Agents

  • L. Szekeres
  • J. Gy. Papp
Conference paper
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 9)

Abstract

Responsiveness to verapamil, the best studied calcium antagonist, was examined in cardiac preparations of rabbits pretreated with β-adrenoceptor blockers (propranolol 2 mg/kg or oxprenolol 4 mg/kg s.c.) twice daily for either one or six weeks. Using this dose-regimen, the degree of cardiac β-adrenoceptor blockade in conscious rabbits was substantial and similar for propranolol and oxprenolol. When administered for one week, neither proranolol nor oxprenolol affected to any marked extent the electrical and mechanical response to verapamil, diltiazem or fendiline in tissues isolated from various parts of the heart. In contrast, pretreatment with propranolol for six weeks resulted in a significant aggravation of the negative inotropic effect of verapamil in both atrial and ventricular muscle, and the verapamil-induced delay in atrio-ventricular and intra-ventricular conduction also became more pronounced. The same long-term administration of oxprenolol, one of the β-blockers with “intrinsic” sympathomimetic activity, did not alter the atrial or ventricular contractile response to verapamil and did not significantly increase the lengthening of atrio-ventricular conduction time occurring in the presence of verapamil It is concluded that from the point of view of adverse direct cardiac interactions with verapamil prolonged administration of oxprenolol appears to be less dangerous than chronic treatment with propranolol. It is also assumed that in those cases in which acute administration of verapamil may be necessary, concomitant chronic blockade of cardiac β-adrenoceptors is less dangerous if drugs known to possess not only β-adrenoceptor blocking properties, but also some “intrinsic” sympathomimetic activity are applied.

Key words

Cardiotoxicity Adverse drug interaction Negative inotropic effect Negative dromotropic effect β-adrenoceptor blockers Calcium antagonist Propranolol Oxprenolol Verapamil Diltiazem Fendiline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Campbell CA, Parratt JR, Kane KA, Bullock G (1984) Effects of prolonged administration of oxprenolol on severity of ischaemic arrhythmias, enzyme leakage, infarct size, and intracellular cardiac muscle action potentials. J Cardiovasc Pharmacol 6: 369–377PubMedCrossRefGoogle Scholar
  2. Ellrodt AG, Singh BN (1983) Clinical applications of slow channel blocking compounds. Pharmac Ther 23: 1–43CrossRefGoogle Scholar
  3. Freedberg AS, Papp JGy, Vaughan-Williams EM (1970) The effect of altered thyroid state on atrial intracellular potentials. J Physiol 207: 357–369PubMedGoogle Scholar
  4. Glossmann H, Ferry DR, Lübbecke F, Mewes R, Hofmann F (1982) Calcium channels: direct identification with radioligand binding studies. Trends Pharm Sci 3: 431–437CrossRefGoogle Scholar
  5. Kendall MJ, Beeley L (1983) Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions. Pharmac Ther 21: 351–369CrossRefGoogle Scholar
  6. Nayler WG, Horowitz JD (1983) Calcium antagonists: a new class of drugs. Pharmac Ther 20: 203–262CrossRefGoogle Scholar
  7. Nelson GIC, Silke B, Ahuja RC, Hussain M, Forsyth D, Taylor SH (1984) The effect on left ventricular performance of nifedipine and metoprolol singly and together in exercise-induced angina pectoris. Eur Heart J 5: 67–79PubMedGoogle Scholar
  8. Opie LH (1984) Calcium ions, drug action and the heart — with special reference to calcium antagonist drugs. Pharmac Ther 25: 271–295CrossRefGoogle Scholar
  9. Papp JGy, Vaughan-Williams EM (1969) The effect of bretylium on intracellular cardiac action poten- tials in relation to its anti-arrhythmic and local anaesthetic activity. Br J Pharmac 37: 380–390Google Scholar
  10. Papp JGy, Szekeres L (1972) Cardiac electrophysiological changes due to oxyfedrine. In: Gerlach E, Moser K (eds) Action of oxyfedrine. Schattauer, Stuttgart New York, pp 3–12Google Scholar
  11. Papp JGy, Vaughan-Williams EM (1969) The effect of bretylium on intracellular cardiac action poten- tials in relation to its anti-arrhythmic and local anaesthetic activity. Br J Pharmac 37: 380–390Google Scholar
  12. Pfisterer M, Muller-Brand J, Burkart F (1982) Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischaemia-induced left ventricular dysfunction. Am J Cardiol 49: 1259–1266PubMedCrossRefGoogle Scholar
  13. Raine AEG, Vaughan-Williams EM (1981) Adaptation to prolonged ß-blockade of rabbit atrial, Purkinje and ventricular potentials, and of papillary muscle contraction. Circ Res 48: 804–812Google Scholar
  14. Raine AEG, Vaughan-Williams EM (1980) Adaptational responses to prolonged ß-adrenoceptor blockade in adult rabbits. Br J Pharmac 70: 205–218Google Scholar
  15. Szekeres L, Papp JGy (1971) Experimental cardiac arrhythmias and antiarrhythmic drugs. Akadémiai Kiadó, BudapestGoogle Scholar
  16. Szekeres L, Vaughan-Williams EM (1962) Antifibrillatory action. J Physiol 160: 470–482PubMedGoogle Scholar
  17. Szentmiklósi AJ, Németh M, Szegi J, Papp JGy, Szekeres L (1980) Effect of adenosine on sinoatrial and ventricular automaticity. Naunyn-Schmiedeberg’s Arch Pharmacol 311: 147–149PubMedCrossRefGoogle Scholar
  18. Winniford MD, Markham RV, Firth BG, Nicod P, Hillis LD (1982) Haemodynamic and electro physiologic effects of verapamil and nifedipine in patients on propranolol. Am J Cardiol 50: 704–710PubMedCrossRefGoogle Scholar
  19. Wollemann M, Borbola J, Papp JGy, Szekeres L (1975) Cardiac adenylate cyclase activity in relation to beta-adrenergic responses. J Mol Cell Cardiol 7: 523–533PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • L. Szekeres
    • 1
  • J. Gy. Papp
    • 1
  1. 1.Department of PharmacologyUniversity Medical School of SzegedSzegedHungary

Personalised recommendations